Oxulumis™ is a proprietary, semi-automated ocular administration device utilizing an advantageous route of administration (the suprachoroidal space) to deliver therapeutics for the treatment of retinal diseases.
Oxulumis™ offers physicians a novel, less invasive administration procedure.
Administration is straightforward: similar to an intravitreal injection, it is performed in approximately one to two minutes and requires no ancillary equipment.
The device is engineered to deliver retinal therapeutics through a specially designed microcatheter, which is deployed into the posterior region of the suprachoroidal space. The microcatheter is illuminated allowing trans-scleral visualization by direct observation. This provides absolute confirmation of accurate placement of the microcatheter. The microcatheter is also lubricious and flexible to promote advancement, and employs an atraumatic (soft) tip to promote safety.
A small-gauge needle, which accommodates variation in scleral thickness across most patients, is inserted in the pars plana of the eye. As the needle advances, the microcatheter deploys automatically once the tip of the needle reaches the suprachoroidal space. The microcatheter advances posteriorly in the suprachoroidal space toward the macula, where the drug product will be delivered.
Once accurate placement of the illuminated microcatheter along the posterior retina is confirmed by the physician, the drug product can be accurately and safely delivered. The drug product is deposited at the deployment site and the natural physiological flows of the suprachoroidal space move the drug product posteriorly.
Key features of Oxulumis™ suprachoroidal space microcatheter
- Proprietary, semi-automated ocular administration device
- Utilizes the suprachoroidal space, which is an advantageous route of administration to specific tissues involved in retinal disease
- Pars plana site administration
- Delivers therapeutics via an illuminated microcatheter to posterior segment of the suprachoroidal space
- Visual confirmation of microcatheter placement in suprachoroidal space to ensure 100% accurate drug delivery
Key benefits of Oxulumis™ suprachoroidal space microcatheterization
- Minimally invasive procedure does not penetrate the intraocular space
- Safely delivers long-lasting drug products alongside the posterior retina and macula
- Offers ophthalmologists a novel, site-specific administration procedure, which is efficient in a conventional treatment setting